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Objective: To compare the biocompatibility and immunogenicity of two intra-articular hyaluronan for-
mulations, Gel-200 (Gel-One®) and hylan G-F 20 (Synvisc® series).
Experimental design: A comparison of the biocompatibility of Gel-200 and hylan G-F 20 was made using
a rat subcutaneous air pouch model and the knee joint of normal rabbits. Immunogenicity was evaluated
using a homologous passive cutaneous anaphylaxis (PCA) assay in guinea pigs.
Results: In the air pouch model in rats, characteristic ﬁbrous belts formed in the subcutaneous tissue.
Injection of hylan G-F 20 into the air pouch induced granulomatous nodules primarily composed of
macrophages, multinucleated giant cells, and eosinophils accompanied with the test material in the
center of the nodules in the ﬁbrous belt. Furthermore, the thickness of the ﬁbrous belt in the hylan G-F 20
group increased signiﬁcantly compared to the saline group. Injection of Gel-200 into the air pouch
induced neither granulomatous inﬂammation nor signiﬁcant thickening of ﬁbrous belt, while foamy
macrophages containing the test material were observed. Intra-articular injection of hylan G-F 20 into
the rabbit knee joints induced granulomatous inﬂammation, eosinophil inﬁltration, and signiﬁcant in-
crease in the number of cells in the synovial ﬂuid, while these ﬁndings were absent in the Gel-200 group.
In the immunogenicity assay, hylan G-F 20 induced a positive PCA reaction, but the Gel-200 did not.
Conclusion: Gel-200 showed more favorable biocompatibility and less immunogenicity compared to
hylan G-F 20. Gel-200 is expected to be a single injection hyaluronan product with less safety concerns
for the treatment of knee osteoarthritis (OA) pain.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) of the knee is a common joint disorder in the
aging population. Intra-articular hyaluronic acid (HA) products
have beenwidely accepted as a viscosupplements for the treatment
of knee OA pain1,2. HA products are divided into two major types,
native HA products and cross-linked HA products. Native HA
products are injected 3 to 5 times per treatment course and their
safety has been established based on the results of long-term
clinical use3. In the cross-linked HA category, there are three
products on the US market, Gel-One®, Synvisc® and Synvisc-One®.
Synvisc and Synvisc-One are composed of hylan G-F 20, which is a
mixture of two cross-linked HA derivatives. Synvisc-One was the
ﬁrst single injection product approved in the US and contains three. Urano, Central Research Lab.,
iyamato-shi, Tokyo 207-0021,
no).
ternational. Published by Elsevier Ltimes the volume of hylan G-F 20 as Synvisc, which requires three
injections. However, there is growing clinical evidence to suggest
that hylan G-F 20 may be associated with an increased incidence of
pseudosepsis or granulomatous synovitis4e13. Furthermore, in non-
clinical studies, evidence of an immune response to hylan G-F 20
has been demonstrated. In particular, it has been reported that
hylan G-F 20 exhibited immunogenicity in guinea pigs and certain
strains of mice14, and induced an inﬂammatory tissue response in
the air pouch in mice15. The air pouch model is a well-established
model to test local inﬂammatory and immunological effects16.
Furthermore, it has been reported that normal rabbit knee joints
treated with hylan G-F 20 were slightly inﬂamed17. It appears likely
that the adverse responses in clinical practice may be attributable
to a component of hylan G-F 20. Therefore, safer products requiring
fewer injections would be expected to improve the quality of life for
OA patients.
Gel-One® is a recently approved single injection product for the
treatment of knee OA pain on the US market and is composed of
Gel-200, a novel cross-linked HA hydrogel manufactured by
photo-gelation technology. The strands of HA in Gel-200 aretd. All rights reserved.
Table I
Histological scoring
Histological ﬁnding Score
Granulomatous inﬂammation
with multinucleated
giant cells*
None 0
Slight 1
Moderate 2
Severe 3
Foamy macrophage
inﬁltration*
None 0
Slight 1
Moderate 2
Severe 3
Eosinophil inﬁltration* None 0
Slight 1
Moderate 2
Severe 3
Synovial thickeningy Lining cell layer 1e2 cells thick 0
Lining cell layer 3e5 cells thick 1
Lining cell layer 6e8 cells thick
and/or mild increase in cellularity
2
Lining cell layer >9 cells thick
and/or severe increase in cellularity
3
* Score used for rat air poch model and rabbit knee joint model.
y Score described previously20 and used for rabbit knee joint model.
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irradiation resulting in a clean cross-linked highly viscoelastic
hydrogel. The highly puriﬁed photocurable HA derivative
chemically linked with cinnamic acid, an intermediate of Gel-200,
can be cross-linked by using only ultraviolet irradiation without
any additional condensation reagents. The photo-gelation tech-
nology achieves high puriﬁcation without any elimination process
for residual reagents and/or by-products after cross-linking. In a
multi-center randomized controlled trial in patients with symp-
tomatic OA of the knee, a single injection of Gel-200 was well
tolerated and relieved associated pain for over 13 weeks18. There
have been no reported incidents of pseudosepsis from Gel-200 in
clinical use. The absence of allergic reactions or pseudosepsis and
the low incidence of adverse events associated with this treatment
support the favorable safety proﬁle of Gel-200 for treatment of
symptomatic OA of the knee18.
The objective of this study was to compare the biocompatibility
and immunogenicity of Gel-200 and hylan G-F 20 in non-clinical
models.
Materials and methods
Animals
Female SpragueeDawley rats (8 weeks old; Charles River Lab-
oratories Japan, Inc., Kanagawa, Japan), male New Zealand White
rabbits (11 weeks old; Oriental Yeast Co., Ltd, Tokyo, Japan), and
male Hartley guinea pigs (6 weeks old; Japan SLC, Inc., Shizuoka,
Japan) were utilized in this study. The animals were quarantined
and acclimatized to the environmental conditions for 1 week. The
study protocols were reviewed by the In-house Animal Experiment
Ethics Committee, and after approval, performed under the animal
husbandry/management system in an appropriate environment
with animal protection/welfare in mind.
Air pouch model in rats
Seventy-two rats were anesthetized with isoﬂurane and 20 mL
of air sterilized with a 0.22 mm ﬁlter was injected subcutaneously
into the back. Three days later, an additional 10 mL of air was
injected into the air pouch to maintain the cavity. Six days after the
ﬁrst injection, the rats were allocated to four groups (n ¼ 18) based
on the body weights. Saline, carrageenan (1 w/v%; l-Carrageenan,
Sigma Aldrich, MO, USA), hylan G-F 20 (8 mg/mL; Synvisc®, Gen-
zyme Corporation, NJ, USA), or Gel-200 (10 mg/mL; Gel-One®,
Seikagaku Corporation, Tokyo, Japan) was administered into the air
pouch of animals at 2 mL/body. Fourteen, 28 and 56 days after the
administration, six rats from each group were euthanized. The air
pouch was washed with 10 mL of phosphate buffered saline (PBS)
with 1mM ethylenediaminetetraacetic acid (EDTA), the pouch ﬂuid
was collected, and the total number of cells in the pouch ﬂuid was
counted with a light microscope. For characterization of the cell
types, the pouch ﬂuid was smeared on a slide, stained with Diff-
Quick (Sysmex Corporation, Hyogo, Japan), and observed under a
light microscope. The proportion of the cell proﬁles corresponding
to neutrophils, eosinophils, monocytes or lymphocytes was recor-
ded (n ¼ 6).
For histological examination, pouch tissue was harvested
immediately after the pouch ﬂuid collection, ﬁxed in 10% neutral
buffered formalin, embedded in parafﬁn, and sectioned. The
sections were stained with hematoxylin and eosin (HE) or Movat's
pentachrome (MP). Measurements of the thickness of ﬁbrous
belt and histological scoring were performed independently by
two evaluators under blinded conditions. Intra-observer and
inter-observer reproducibility of the histological scoring wereconﬁrmed. Fibrous belts are observed characteristically in air
pouch models in rats and mice15,16,19 and their thickness is
measured to evaluate the inﬂammatory reaction of biomaterials.
Fibrous belt is deﬁned as a belt-like structure composed of ﬁbro-
blasts and collagenous matrices and formed between the subcu-
taneous connective tissue and pouch cavity; the thickness in
representative area of each slide was measured by cellSens Stan-
dard software (Olympus Corporation, Tokyo, Japan). Furthermore,
as granulomatous inﬂammation with multinucleated giant cells,
foamy macrophage inﬁltration, and eosinophil inﬁltration were
characteristic reactions in the ﬁbrous belt, these ﬁndings were
graded 0e3, according to the scores shown in Table I. In each
group, some slides had to be excluded from histological exami-
nation due to absence of a ﬁbrous belt, which had possibly
sloughed off during lavage ﬂuid collection or the sectioning pro-
cedures. The numbers of evaluated samples were n ¼ 3e6 per
each group.Biocompatibility study in normal rabbit knee joints
Thirty-six rabbits were allocated to six groups (n ¼ 6) based on
the body weights and anesthetized by an intravenous injection of
mixed anesthesia using midazolam (Dormicum, Astellas Pharma
Inc, Tokyo, Japan), xylazine (Selactar 2%, Bayer Yakuhin Ltd., Osaka,
Japan), butorphanol (Vetorphale, Meiji Seika Pharma Co., Ltd.,
Tokyo, Japan), and saline (1:2:1:2) at a volume of 2 mL/body. Three
groups of animals received a single intra-articular injection of
0.25 mL of either saline, Gel-200, or hylan G-F 20 into both knee
joints and the other three groups of animals received three
consecutive weekly intra-articular injections of 0.25 mL of either
saline, Gel-200, or hylan G-F 20 into both knee joints. Fifteen days
after the ﬁrst injection, all the rabbits were euthanized and both
knee joints were collected. From the right knee joints, synovial ﬂuid
was collected by washing the joint cavity three times with 0.5 mL
lavage solution (PBSwith 1mMEDTA). For each sample the number
of total cells, monocytes, lymphocytes, and heterophils in the sy-
novial ﬂuid were determined by the same method as in the air
pouch model in rats (n ¼ 6).
From the left knee joints, the synovium was collected and ﬁxed
in 10% neutral buffered formalin. Fixed samples were processed,
embedded in parafﬁn, sectioned, and stained with HE or MP for
histological examination. Histological scoring was performed
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observer and inter-observer reproducibility of the histological
scoring were conﬁrmed. Granulomatous inﬂammation with
multinucleated giant cells, foamy macrophage inﬁltration, and
eosinophil inﬁltrationwas scored on a 4-point scale of Grades 0 (No
change) to 3 (Severe change). Synovial thickening was scored using
criteria given in a previous report20 (Table I). The numbers of
evaluated samples were n ¼ 6 per each group.
Immunogenicity study in guinea pigs
Immunization and serum collection
An immunogenicity study in guinea pigs was performed as
described by Nagami et al.21 with some modiﬁcations. Thirty-four
guinea pigs were allocated to six groups (n ¼ 6 except for the
positive control group, n ¼ 4) and immunized by subcutaneous
injection of the test material once aweek for 3 weeks as follows: (1)
Gel-200 at 2.5 mg/kg, (2) Gel-200 at 2.5 mg/kg þ an equal volume
of Freund's complete adjuvant (FCA, Difco Laboratories Inc, MI,
USA), (3) hylan G-F 20 at 2.5 mg/kg, (4) hylan G-F 20 at 2.5 mg/
kg þ FCA, (5) ovalbumin (OVA, Sigma Aldrich) at 1.5 mg/
animal þ FCA as a positive control, and (6) non-immunized as a
negative control. FCAwas used only for the ﬁrst immunization, and
incomplete adjuvant was used for the second and third immuni-
zations. Sixteen days after the ﬁnal immunization, bloodwas drawn
from each animal and separated sera were stored at 80C until
analyses described below.
Homologous passive cutaneous anaphylaxis (PCA)
Twelve naive guinea pigs each received six intradermal in-
jections into the dorsal skin of 0.1 mL sera from immunized
animals. Twenty-four hours after injection, each animal was
administered intravenously a corresponding antigen (Gel-200
5 mg/kg, hylan G-F 20 5 mg/kg, or OVA at 1 mg/animal) and Evans
blue dye. Thirty minutes after the elicitation, the animals were
euthanized and the diameters of blue spots that had developed at
the serum injection sites were measured. When a blue spot was
>5 mm in diameter, the PCA reaction was considered positive and
further diluted serum was tested in other naive animals to
determine the maximal PCA titer of the serum. Each serum was
tested in two naive recipients to conﬁrm the reproducibility of the
reactions.
Statistical analyses
Statistical analyses were performed using SAS (SAS Institute Inc.,
NC, USA). The effects from treatment with saline, Gel-200, hylan G-
F 20, or carrageenan were analyzed by the following multiple
comparison tests. One-way analysis of variance (ANOVA) with
Dunnett's test was used for the thickness of the ﬁbrous belt and cell
numbers in the lavage ﬂuid. KruskaleWallis with Steel's test was
used for histological scores. Results were represented as mean and
95% conﬁdence intervals (CI). Any P-values of <0.05 were consid-
ered statistically signiﬁcant.
Results
Histological analysis of the rat air pouch model
In the saline group at day 14, there were distinctive ﬁbrous belts
composed of ﬁbroblasts and collagenous matrices, which might be
the wall of the air pouch. Average thickness of the ﬁbrous belt at
day 14 was 205 mm (n ¼ 5; 95% CI, 78e333), which decreased at
subsequent time points [Fig. 1(A) and (E)].In the Gel-200 group, the average thickness of the ﬁbrous belt at
day 14 (343 mm (n ¼ 4; 95% CI, 101e585)) was not signiﬁcantly
different from that in the saline group. Granulomatous inﬂamma-
tion and eosinophil inﬁltration were not observed. Signiﬁcant in-
ﬁltrations of foamy macrophages containing test material were
observed in and on the surfaces of the ﬁbrous belts at days 14 and
28 [Fig. 1(C, G, and H)].
In the hylan G-F 20 group, the average thickness of the ﬁbrous
belt at day 14 (789 mm (n ¼ 3; 95% CI, 289e1289)) was signiﬁcantly
higher than that in the saline group (P ¼ 0.002). Thickening of the
ﬁbrous belt tended to resolve at subsequent time points. Further-
more, signiﬁcant granulomatous inﬂammation with multinucle-
ated giant cells (days 14, 28, and 56) and inﬁltration of eosinophils
(days 28 and 56) were observed [Fig. 1(B, D, I and J)].
In the carrageenan group, the average thickness of the ﬁbrous
belt at day 14 (738 mm (n ¼ 5; 95% CI, 426e1050)) was signiﬁcantly
higher than that in the saline group (P ¼ 0.002). Thickening of the
ﬁbrous belt did not resolve at subsequent time points. Foamy
macrophages (days 14, 28, and 56) and eosinophil inﬁltration
(days 14 and 28) were also signiﬁcant [Fig. 1(C) and (D)]. Granu-
lomatous inﬂammation could not be scored in the same grading
system as in the other groups because large-sized and eosinophilic
macrophages without prominent multinucleated giant cell accu-
mulation were prevalent in the carrageenan group and, though the
degree of inﬂammation was severe [Fig. 1(F)], these ﬁndings were
different from the typical granulomatous inﬂammation seen in the
hylan G-F 20 group.Pouch ﬂuid cell count
In the Gel-200 group, the average number of total cells, lym-
phocytes, and monocytes increased at day 14, and decreased after
day 28, though these changes were not signiﬁcant compared to the
saline group (Table II).
In the hylan G-F 20 group, the average number of total cells,
lymphocytes, and monocytes increased at day 14, and decreased
after day 28, though these changes were not signiﬁcant compared
to the saline group. Eosinophil inﬁltration was observed in only the
hylan G-F 20 group at days 14 and 28.
In the carrageenan group, the average number of total cells,
lymphocytes, monocytes, and neutrophils were signiﬁcantly
increased compared to the saline group at multiple time points.Histological analysis of normal rabbit knee joints
In the saline group, no abnormalities were detected in the
synovium in both the single- and three-injection regimens
[Fig. 2(AeE)].
In the Gel-200 group, slight proliferation of the synovial cells
and fragments of the test material in the adipose tissue with
inﬁltration of macrophages were seen [Fig. 2(A) and (F)]. Foamy
macrophage inﬁltration scorewas increased signiﬁcantly compared
to the saline group in the three-injection regimen [P ¼ 0.01;
Fig. 2(C)]. Granulomatous inﬂammation and eosinophil inﬁltration
were not observed.
In the hylan G-F 20 group, the synovial cells showed similar
changes to the Gel-200 group. Granulomatous inﬂammation
with multinucleated giant cells emerged in both single-
[Fig. 2(G)] and three-injection (photomicrographs not shown)
regimens, though changes in the scores were not signiﬁcantly
different from the saline group. Eosinophil inﬁltration score was
signiﬁcantly higher than the saline group in the three-injection
regimen [P ¼ 0.004; Fig. 2(D)], while foamy macrophage inﬁl-
tration was not detected.
Fig. 1. Histological evaluation of the air pouch in rats after injection of four different samples. Values represent the means ± 95% CI (n ¼ 3e6). (A) Thickness of ﬁbrous belt was
increased in the hylan G-F 20 (**P ¼ 0.002) and carrageenan group (**P ¼ 0.002) compared to the saline group at day 14. On days 28 and 56, only the carrageenan group showed
signiﬁcant increase (***P < 0.001 for both). (B) The score for granulomatous inﬂammation with multinucleated giant cells was higher in all three time points in the hylan G-F 20
(*P ¼ 0.02, 0.01, and 0.02 at days 14, 28, and 56, respectively) compared to the saline group. N.D.: not determined. (C) The foamy macrophage inﬁltration score was increased in the
Gel-200 group at days 14 (*P ¼ 0.02) and 28 (*P ¼ 0.02) and in the carrageenan group at days 14 (**P ¼ 0.008), 28 (*P ¼ 0.02), and 56 (*P ¼ 0.02) compared to the saline group. (D)
The eosinophil inﬁltration score was increased in the hylan G-F 20 group at days 28 (*P ¼ 0.01) and 56 (**P ¼ 0.005) and in the carrageenan group at days 14 (*P ¼ 0.01) and 28
(*P ¼ 0.02) compared to the saline group. (EeJ) Histological appearance of the rat air pouches at day 14. (E) In the saline group, ﬁbrous belt composed of ﬁbroblasts and collagenous
matrices is seen (HE  40). (F) In the carrageenan group, accumulation of large-sized macrophages and granulomatous inﬂammation are seen in the upper-half of the ﬁgure. A
mature ﬁbrous belt with inﬂammatory cells is seen in the lower-half of the ﬁgure (HE  40). (G and H) In the Gel-200 group, foamy macrophages (arrowheads) containing the test
article (asterisks, stained blue in (H)) are seen in and on the surface of the ﬁbrous belt (G; HE stain  40, H; MP stain  40). (I and J) In the hylan G-F 20 group, granulomatous
nodules (arrows) primarily composed of macrophages, multinucleated giant cells, and eosinophils (arrowheads) accompanied with the test article (asterisks, stained blue in (J)) in
the center of the nodules are seen in the ﬁbrous belt (I; HE stain  40, J; MP stain  40). Scale bars: 50 mm (EeJ).
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In the Gel-200 group, neither single- nor three-injection
induced signiﬁcant increase of any types of cells in the synovial
ﬂuid (Fig. 3).In the hylan G-F 20 group, single-injection tended to increase
the average number of cells in the synovial ﬂuid but not signiﬁ-
cantly (total cells; P ¼ 0.06) compared to those of the saline
[Fig. 3(A)]. Three consecutive weekly injections of hylan G-F 20
signiﬁcantly increased the average number of total cells (3.8  106
Table II
Cell recruitment in the air pouch after injection of four different samples
The number of cells/days after administration
14 days 28 days 56 days
Total cell
Saline 7.0 ± 5.0  104 7.8 ± 9.5  103 4.6 ± 1.9  103
Gel-200 4.4 ± 2.4  106 4.3 ± 6.1  104 9.0 ± 18.0  104
Hylan G-F 20 5.3 ± 2.9  106 5.7 ± 7.0  104 6.9 ± 10.4  104
Carrageenan 5.3 ± 2.7  107*** 3.8 ± 4.4  107* 2.1 ± 3.1  107
Lymphocyte
Saline 2.7 ± 3.2  104 3.1 ± 3.1  103 1.4 ± 0.6  103
Gel-200 3.5 ± 1.9  105 3.7 ± 2.1  103 2.5 ± 5.1  104
Hylan G-F 20 6.4 ± 5.9  105 9.9 ± 6.9  103 2.1 ± 3.2  104
Carrageenan 9.5 ± 11.9  106* 5.0 ± 3.4  106*** 6.5 ± 10.6  106
Monocyte
Saline 4.3 ± 2.5  104 4.8 ± 6.5  103 3.2 ± 1.4  103
Gel-200 4.0 ± 2.3  106 4.0 ± 5.9  104 6.4 ± 13.0  104
Hylan G-F 20 3.9 ± 1.8  106 4.4 ± 6.8  104 4.7 ± 7.2  104
Carrageenan 3.8 ± 1.6  107*** 2.9 ± 3.5  107* 1.2 ± 1.7  107
Neutrophil
Saline 0 0 0
Gel-200 0 0 0
Hylan G-F 20 0 0 0
Carrageenan 5.5 ± 5.5  106** 4.2 ± 7.2  106 2.4 ± 3.4  106
Eosinophil
Saline 0 0 0
Gel-200 0 0 0
Hylan G-F 20 7.9 ± 13.3  105 2.9 ± 5.7  103 0
Carrageenan 0 0 0
Values represent themeans± 95% CI (n¼ 6). *P < 0.05, **P < 0.01, and ***P < 0.001 vs
saline for each time point.
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(n¼ 6; 95% CI, 0.7e3.7 106); P¼ 0.008), and heterophils (1.0 106
(n ¼ 6; 95% CI, 0.2e2.3  106); P ¼ 0.03) compared to the saline
group [Fig. 3(B)].Homologous PCA
All animals in the positive control group challenged with OVA
showed positive PCA reactions, which conﬁrmed adequate immu-
nization (Table III). In both the Gel-200 and Gel-200 þ FCA groups,
sera from the immunized animals induced no PCA reaction. On the
other hand, sera from animals immunized with hylan G-F 20 (1/6)
or hylan G-F 20 þ FCA (5/6) induced positive PCA reactions in the
recipient guinea pigs. Maximal PCA titers of the sera were 10 and 1
in the hylan G-F 20 and hylan G-F 20 þ FCA groups, respectively.Discussion
Non-cross-linked HA has long been used to reduce pain in OA
patients with a favorable safety proﬁle22,23. Cross-linked HA is a
newer class of intra-articular injection for the treatment of knee OA.
Cross-linking is intended to render longer-lasting efﬁcacy to HA by
increasing the viscoelasticity and resistance to degradation in the
knee joint tissues. The ﬁrst cross-linked HA product, Synvisc®
composed of hylan G-F 20, has been approved and used in the US
since 199724. However, there is growing evidence to suggest that
hylan G-F 20 may be associated with an increased incidence of
severe acute inﬂammatory reaction that is clinically distinct from
the local inﬂammatory reactions seen with non-cross-linked
HA4e10. Recently, another type of cross-linked HA product, Gel-
200, has been approved. Therefore, it was decided to assess the
biocompatibility and immunogenicity of Gel-200 and hylan G-F 20
in non-clinical studies.
In both the rat subcutaneous air pouch and rabbit knee joint
models, Gel-200 showed higher biocompatibility compared tohylan G-F 20. Histologically, there was no evidence of apparent
toxicity due to Gel-200. Tissue reactions such as phagocytosing
foamy macrophages in the rat air pouch model and slight prolif-
eration of synovial cells in the rabbit knee joint seen in the Gel-200
groups were within the limits of what should be expected with a
normal biological response against biodegradable and semi-solid
materials25,26. As for the cell counts in synovial ﬂuid in rabbits,
the pattern of cell recruitment in Gel-200-treated animals was
almost the same as in the saline group, not only after single in-
jection but also after repeated injections. Schiavinato et al. evalu-
ated the biocompatibility of non-cross-linked HA products, Hyalgan
and Artz, in the same rabbit model as used in this study and
revealed that both materials did not increase the number of in-
ﬂammatory cells in the synovial ﬂuid17. These results suggest that
biocompatibility of Gel-200 may be comparable to non-cross-
linked HA products, which requires further study for direct com-
parison of Gel-200 with non-cross-linked HA products.
Compared to Gel-200, hylan G-F 20 showed several different
ﬁndings in both the rat and rabbit models. First, signiﬁcant increase
in ﬁbrous belt thickness was seen after the injection of hylan G-F 20
into the rat air pouch, which may be attributed to formation of
granulomatous nodules in the ﬁbrous belt. In the Gel-200 group,
thickening of the ﬁbrous belt was not statistically signiﬁcant.
Similar results were reported in the mouse air pouch model15,19,
where marked ﬁbroblastic responses together with air pouch
membrane thickening were detected in hylan G-F 20-injected an-
imals. Second, granulomatous inﬂammation with multinucleated
giant cells appeared in the rat air pouch and in the rabbit knee joint.
Hylan G-F 20-related granulomatous reactions were reported in
guinea pigs after intradermal administration27 and in patients
treated with repeated intra-articular administrations11e13. How-
ever, the association between hylan G-F 20 and granulomatous
reaction in the clinical setting remains controversial since a recent
report argues that granulomas can be expected to occur in the
progression of OA without hylan G-F 20 injection28. Given the
limited opportunities for histological examination in patients, the
non-clinical models used in this study will help in the prediction of
clinical safety proﬁling of intra-articular HA products. Third, as for
the recruitment of cells in pouch lavage ﬂuid, eosinophils were
observed only in the hylan G-F 20 group. Furthermore, hylan G-F 20
caused signiﬁcant cell increase after repeated injection into the
rabbit knee joints, which was not observed in the Gel-200 group.
Similar observations were reported by Schiavinato et al.17, where
three weekly injections of hylan G-F 20 into rabbit knee joints
increased total cell numbers in the synovial ﬂuid at 15 days post-
injection whereas those of native HA products did not.
In the immunogenicity assay in guinea pigs, serum from Gel-
200-sensitized animals did not induce a PCA reaction even when
combined with adjuvant. Guinea pigs are one of the most effective
species for detecting the immunogenicity of non-human macro-
molecules with a molecular weight greater than 500029. PCA has
the advantage of measuring not only the biologically active anti-
bodies but also the consequences of allergen/antibody interactions
leading to inﬂammatory mediator release from mast cells and the
expression of cutaneous anaphylaxis. Therefore, the lack of
immunogenicity of Gel-200 in guinea pigs indicated that the risk of
allergic reaction caused by Gel-200 is expected to be very low.
Serum from hylan G-F 20-sensitized guinea pigs induced posi-
tive PCA reactions in recipient animals, which was comparable to
results of previous studies showing positive PCA reaction by hylan
G-F 20 in mice and guinea pigs14,27. Guinea pig homologous PCA is
used as a biological assay of sera to detect antigen-speciﬁc IgG1 and
IgE30. For IgE production, Th-2 cytokines such as IL-4, and 13 are
essential31. In addition, another Th-2 cytokine, IL-5, has been
recognized as the major maturation and differentiation factor for
Fig. 2. Histological evaluation of rabbit knee joints after injection of three different samples. Values represent the means ± 95% CI (n ¼ 6). (A) The average synovial thickening score
was increased in the Gel-200 and hylan G-F 20 group, but not signiﬁcantly so compared to the saline group. (B) Granulomatous inﬂammation with multinucleated giant cells was
observed only in the hylan G-F 20 group but change in the score was not signiﬁcant. (C) Foamy macrophage inﬁltration score was increased signiﬁcantly in the Gel-200 group
compared to the saline group in three-injection regimen (**P ¼ 0.0098). (D) Eosinophil inﬁltration was observed in the hylan G-F 20 group and signiﬁcantly higher than the saline
group in three-injection regimen (**P ¼ 0.004). (EeG) Histological appearance of characteristic tissue reaction around test samples 15 days after single administration (HE  40). (E)
In the saline group, no abnormalities were observed. (F) In the Gel-200 group, fragments of the test article (asterisks) with inﬁltration with macrophages in the adipose tissue are
seen. (G) In the hylan G-F 20 group, granulomatous nodules with multinucleated giant cells (arrow) and eosinophils (arrowheads, distinguished from neutrophils histologically),
which were accompanied by the test article (asterisk) in the center of the nodules, were seen in the adipose tissue. Scale bars: 50 mm (EeG).
M. Ishikawa et al. / Osteoarthritis and Cartilage 22 (2014) 1902e1909 1907eosinophils32. Given that both positive PCA reaction and eosinophil
inﬁltrations were observed in the present study, it is suggested that
hylan G-F 20 may induce Th-2 type response.
The differences in biocompatibility and immunogenicity be-
tween Gel-200 and hylan G-F 20 shown in this study may be due to
a difference in the cross-linking technology between the two
products. Gel-200 is composed of cross-linked HA, a derivative of a
highly puriﬁed sodium HA product extracted from chicken combs
and strands of HA are bound to each other via dimers of cinnamic
acid resulting in increased viscoelasticity25. On the other hand,
hylan G-F 20 is composed of 80% hylan A and 20% hylan B. Hylan A is
prepared by bridging HA molecules using formaldehyde and pro-
teins derived from chicken combs, which results in viscous ﬂuid
fraction33. Hylan B is prepared by forming cross-links between
hylan A or HA using vinylsulfone, which results in globule gel-like
fraction33e35. The different link structures bridging HA, namely,
cinnamic acid derivative in Gel-200 and protein and vinylsulfone
derivatives in hylan G-F 20, may have resulted in the biocompati-
bility differences seen in rats and rabbits.
A possible explanation for the difference in macrophage
response between Gel-200 and hylan G-F 20 is the difference in
physicochemical character such as particle size. In fact, biomaterialwith small particle size (<10 mm) is considered to be degraded
within phagosomes after phagocytosis, while biomaterial with
large particle size (between 10 mm and several hundred microme-
ters) could not be phagocytosed by single-nucleated macrophages,
leading to fusion of macrophages into multinucleated foreign body
giant cells to engulf the particle26. Particle-free property of Gel-200
might result in the inﬁltration of foamy phagocytosing macro-
phages whereas relatively large particle size (z500 mm) of hylan B
gel in hylan G-F 2033,36 might result in the formation of multinu-
cleated giant cells.
The differences in immunogenicity between Gel-200 and hylan
G-F 20 may be attributed to residual protein amount, which is
supported by results of previous studies4,23,35,37. Puttick et al. were
the ﬁrst to document severe acute inﬂammatory reactions in pa-
tients treated with hylan G-F 20 and to detect signiﬁcant antibody
titers to chicken serum proteins in the serum of one of his patients4.
Bucher et al. described the presence of anti-chicken protein anti-
body in the serum of hylan G-F 20 immunized rabbits37. Further-
more, Ohshima et al. observed that residual protein amounts were
larger with hylan G-F 20 thanwith other HA products35. From these
points of view, it was assumed that the relatively higher levels of
chicken protein used for cross-linking may have caused the
Fig. 3. Cell recruitment in the synovial ﬂuid in rabbits after single (A) or three weekly
(B) injections of three different samples. Values represent the means ± 95% CI (n ¼ 6).
(A) Marginal increases compared to the saline group were observed for total cells
(P ¼ 0.06), monocytes (P ¼ 0.06), and lymphocytes (P ¼ 0.09) in the hylan G-F 20
group. (B) Total cells (*P ¼ 0.01), monocytes (**P ¼ 0.008), and heterophils (*P ¼ 0.03)
were signiﬁcantly increased in the hylan G-F 20 group compared to the saline group.
Gel-200 did not showed signiﬁcant increases in cell numbers in either treatment
regimen.
M. Ishikawa et al. / Osteoarthritis and Cartilage 22 (2014) 1902e19091908increased immunogenicity to hylan G-F 20. In Gel-200, chicken
proteins are not used as cross-linkers, which may explain the
absence of immunogenicity in the present study.
One of the limitations of the current study is the relatively small
sample size (six animals per group). Especially in the rabbit knee
joint study, occurrence of granulomatous reaction was limited to
1e3 per six animals in the hylan G-F 20 group. Thus, the changewas
not statistically signiﬁcant. Low incidence of the granulomatous
reaction in the rabbit knee joint may reﬂect the clinical results of
hylan G-F 20 with generally well-tolerated proﬁle with incidentalTable III
Homologous PCA responses in naïve guinea pigs
Immunization,
mg/kg BW
Challenge,
mg/kg BW
No. of
positive sera
Maximal PCA
titers
Gel-200, 2.5 Gel-200, 5 0/6 e
Gel-200, 2.5 þ FCA Gel-200, 5 0/6 e
Hylan G-F 20, 2.5 Hylan G-F 20, 5 01/6 10
Hylan G-F 20, 2.5 þ FCA Hylan G-F 20, 5 5/6 1
OVA* þ FCA OVAy 4/4 1000e10,000
Non-immunized Gel-200, 5 0/2 e
Hylan G-F 20, 5 0/2 e
OVAy 0/2 e
* 1.5 mg/animal.
y 1 mg/animal. BW: body weight.reports of severe acute inﬂammatory reactions8. Another limitation
is that, in the rat air pouch model, the lavage ﬂuid collection and
histological sectioning were performed on the same sample, which
may be the reason for the loss of several samples for histological
evaluation, leading to sample size of 3e6 per group. Nevertheless,
clear differences of histological scores between groups in air pouch
model suggest that sample size difference would not change the
conclusion of the present study.
In conclusion, Gel-200 showed awell-tolerated proﬁle in animal
models where hylan G-F 20 induced inﬂammation and showed
immunogenicity to a similar extent as previously reported. Coupled
with a recent report from a randomized controlled trial of Gel-200,
where pseudosepsis and allergic reactions were not reported for
any of the 249 analyzed patients18, the biocompatible and non-
immunogenic ﬁndings of Gel-200 in this study support a favor-
able safety proﬁle for this cross-linked HA product for the treat-
ment of knee OA.
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